Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration

Purpose. To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration. Methods. This retrospective st...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Ophthalmol
Huvudupphovsmän: Griffin, David R., Richmond, Preston P., Olson, John C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Hindawi Publishing Corporation 2014
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258314/
https://ncbi.nlm.nih.gov/pubmed/25505976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/497178
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk